

## **Activity induced by a danazol derivative on perfusion pressure and coronary resistance in isolated rat heart**

<sup>1</sup>Figueroa-Valverde Lauro\*, <sup>2</sup>Díaz-Cedillo Francisco, <sup>1</sup>Lopez-Ramos Ma, <sup>1</sup>Garcia-Cervera Elodia.

<sup>1</sup>Laboratorio de Investigación de la Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Campeche, Av. Agustín Melgar, Col Buenavista C.P.24039 Campeche Cam., México. lauro\_1999@yahoo.com

<sup>2</sup>Laboratorio de Química Orgánica de la Esc. Nal. de Ciencias Biológicas del Instituto Politécnico Nacional. Prol. Carpio y Plan de Ayala s/n Col. Santo Tomas, México, D.F. C.P. 11340. stybium@yahoo.com

### **Abstract**

**Experimental studies suggest that danazol can be associated with changes in blood pressure. Nevertheless, there is scarce information about the effects of danazol and its derivatives at cardiovascular level. To clarify on this phenomenon, we evaluated the effects of danazol derivative on perfusion pressure in isolated rat heart using Langendorff flow model. Our results demonstrated that pregnenolone-derivative ( $10^{-9}$  mM) significantly increase the perfusion pressure ( $p = 0.05$ ) and vascular resistance ( $p = 0.05$ ) in isolated heart. The activity induced by danazol derivative on perfusion pressure ( $10^{-9}$  to  $10^{-4}$  mM) was blocked in presence of nifedipine ( $10^{-6}$  mM). These data suggest that activity induced by danazol derivative on perfusion pressure and vascular resistance is dependent upon its chemical structure. This phenomenon involves the L-type calcium channel activation through a non-genomic molecular mechanism.**

**Key words:** Danazol, derivative, Langendorff, perfusion pressure.

*Accepted February 15 2011*

### **Introduction**

High blood pressure contributes substantially to cardiovascular disease incidence and premature mortality [1,2]. Studies using the technique of ambulatory blood pressure monitoring have shown that blood pressure is higher in men than in women of similar ages [3,4]. Experimental and clinical studies [5-7] has demonstrated that androgens can be associated with hypertension development. In particular, there are some reports which indicate that danazol is associated with hypertension [8]. For example the studies reported by Wu and coworkers [9] who suggest that there is a relationship between the danazol and hypertension. These data are supported by the studies of Bretza and coworkers [10]. which indicate that administration of danazol increase the blood pressure, this phenomenon was associated with changes in the sodium levels. Nevertheless, it is important to mention that other clinical data show that activity induced by danazol could be an independent factor of hypertension associated to arterial thrombosis [11].

Recently, a study [12] showed that a danazol derivative (hemisuccinate of danazol) increases the perfusion pressure and resistance vascular in isolated rat heart via interaction of androgen-receptor.

Apart from the above experiments, which also do not show clearly the cellular site and actual molecular mechanisms of danazol and its derivatives, data information are needed for characterizing the activity induced by this steroid and its derivatives at cardiovascular level. To provide this information, the present study was designed to investigate the effects of danazol and the danazol derivative (PDE) on perfusion pressure and coronary resistance in isolated rat hearts using Langendorff model [13]. Additionally, the molecular mechanism involved in the activity induced by PDE on perfusion pressure was evaluated using several substances such as flutamide (androgen receptor antagonist) [14], prazosin ( $\alpha_1$  adrenoreceptor antagonist) [15], metoprolol (selective  $\beta_1$  receptor blocker) [16] and nifedipine (antagonist calcium channel type L) [17] as pharmacological tools.

### **Material and Methods**

#### **General methods**

All experimental procedures and protocols used in this investigation were reviewed and approved by the Animal Care and Use Committee of Universidad Autonoma de Campeche (UAC) and were in accordance with the Guide

for the Care and Use of Laboratory Animals [18]. Male rats (Wistar; weighing 200-250 g; n = 63) were obtained from UAC.

### Reagents

*Pregnenolone-danazol-ethylendiamine* conjugate (succinic acid 6-[2-amino-ethylamino)-methyl]-2-ethynyl-10a,12a-di-methyl-2,3,3-3b-,5,10,10a,10b,11,12,12a, dodecahydro-1H-7-oxa-8-aza-dicyclopenta[*a,h*] phenanthren-1-yl-ester-17-acetyl,10,13-dimethyl-2,3,4,7,8,9, 10,11, 12, 13,14,15,16,17-tetradecahydro-1-H-cyclopenta [*a*] phenanthren- 3-yl ester) showed in Figure 1 was prepared according to a previously reported method by Figueroa and coworkers [19]. Other reagents were obtained from Sigma-Aldrich Chemical Co. All drugs were dissolved in methanol and different dilutions were obtained using Krebs-Henseleit solution (0.01%, v/v).

### Langendorff method

Briefly, the male rat (200 - 250 g) was anesthetized by injecting them with pentobarbital at a dose of 50 mg/Kg body weight. The chest was opened and a loose ligature passed through the ascending aorta. The heart was then rapidly removed and immersed in ice cold physiologic saline solution. The heart was trimmed of non-cardiac tissue and retrograde perfused via a noncirculating perfusion system at a constant flow rate. The perfusion medium was the Krebs-Henseleit solution (pH 7.4, 37°C) composed of (mM); 117.8 NaCl; 6 KCl; 1.75 CaCl<sub>2</sub>; 1.2 NaH<sub>2</sub>PO<sub>4</sub>; 1.2 MgSO<sub>4</sub>; 24.2 NaHCO<sub>3</sub>; 5 glucose and 5 sodium pyruvate. The solution was actively bubbled with a mixture of O<sub>2</sub>/CO<sub>2</sub> (95:5).

The coronary flow was adjusted with a variable-speed peristaltic pump. An initial perfusion rate of 15 ml/min for 5 min was followed by a 25 min equilibration period at a perfusion rate of 10 ml/min. All experimental measurements were done within the equilibration period.

### Perfusion pressure

Evaluations of perfusion pressure changes induced by drugs in this study were assessed using a pressure transducer connected to the chamber where the hearts were mounted and the results entered into a computerized data capture system (Biopac).

### Biological evaluation

#### *Effect induced by pregnenolone, danazol and PDE on perfusion pressure.*

Time course changes in perfusion pressure of pregnenolone, danazol and PDE at a concentration of 10<sup>-9</sup> mM were determined. The effects were obtained in isolated hearts perfused at a constant-flow rate of 10 ml/min. It is important to mention that conditions used were mainly the previous reports [20].

#### *Evaluation of effects exerted by pregnenolone, danazol and PDE on coronary resistance.*

The coronary resistance in absence (control) or presence of pregnenolone, danazol and PDE at a concentration of 10<sup>-9</sup> mM was evaluated. The effects were obtained in isolated hearts perfused at a constant flow rate of 10 ml/min. The coronary resistance was determined by the relationship between coronary flow and perfusion pressure (mm Hg/ml/min) [21,22].

#### *Effects induced by PDE on perfusion pressure through androgen receptors.*

Intracoronary boluses (50 µl) of PDE [10<sup>-9</sup> to 10<sup>-4</sup> mM] were administered and the corresponding effect on the perfusion pressure was determined. The dose-response curve (control) was repeated in the presence of flutamide at a concentration of 10<sup>-6</sup> mM (duration of preincubation with flutamide was by a 10 min equilibration period). The dose of adrenergic antagonist was using previous reports<sup>23</sup>

#### *Effect exerted by PDE on perfusion pressure in the presence of α<sub>1</sub> adrenergic blocker.*

The boluses (50 µl) of PDE [10<sup>-9</sup> to 10<sup>-4</sup> mM] were administered and the corresponding effect on the perfusion pressure was evaluated. It is important to mention that the bolus injection administered was done in the point of cannulation. The dose-response curve (control) was repeated in the presence of prazosin at a concentration of 10<sup>-6</sup> mM (duration of preincubation with prazosin was by a 10 min equilibration period). The dose of α<sub>1</sub> adrenergic antagonist was using the reports by Figueroa<sup>23</sup> Drew [24].

#### *Effects induced by PDE on perfusion pressure in the presence of β<sub>1</sub> adrenergic blocker.*

The boluses (50 µl) of PDE [10<sup>-9</sup> to 10<sup>-4</sup> mM] were administered and the corresponding effect on the perfusion pressure was evaluated. The dose-response curve (control) was repeated in the presence of metoprolol at concentration of 10<sup>-6</sup> mM (duration of preincubation with metoprolol was by a 10 min equilibration period). The dose of β<sub>1</sub> adrenergic antagonist was using previous reports [21,22,25].

#### *Activities exerted by PDE on perfusion pressure in the presence of calcium channel blocker.*

The boluses (50 µl) of PDE [10<sup>-9</sup> to 10<sup>-4</sup> mM] were administered and the corresponding effect on the perfusion pressure was evaluated. The dose-response curve (control) was repeated in the presence of nifedipine at a concentration of 10<sup>-6</sup> mM (duration of preincubation with nifedipine was by a 10 min equilibration period). The dose of calcium antagonist was using previous reports [24].

#### *Statistical analysis*

The obtained values are expressed as mean ± SE (standard error), using each heart as its own control. The comparison between means was made with a paired Stu-

dent's t test. In the case multiple comparison was used an analysis of variance (ANOVA) using the Bonferroni correction factor<sup>26</sup>. The differences were considered significant when  $p$  was equal or smaller than 0.05.

## Results

In this study, the activity induced by danazol, pregnenolone and pregnenolone-danazol-ethylendiamine conjugate (PDE) on perfusion pressure and coronary resistance in isolated rat heart was evaluated. The results obtained from changes in perfusion pressure as a consequence of increases in the time (3-18 min) in absence (control) or in

presence of pregnenolone, danazol and PDE (Figure 2), showed that PDE [ $10^{-9}$  mM] significantly increase the perfusion pressure ( $p = 0.05$ ) in comparison with the control conditions, pregnenolone and danazol at the same dose. Additionally, another result showed that coronary resistance, calculated as the ratio of perfusion pressure at coronary flow assayed (10 ml/min) was higher in the presence of PDE than in control conditions, pregnenolone and danazol ( $p = 0.05$ ) at a concentration of  $10^{-9}$  mmol (Figure 3). Another result (Figure 4) showed that PDE increase the perfusion pressure in a dose dependent manner [ $10^{-9}$  to  $10^{-4}$  mM] and this effect was not inhibited in presence of flutamide [ $10^{-6}$  mM].




Figure 1. Chemical structure of pregnenolone-danazol-ethylendiamine.




Figure 2. Effect induced by pregnenolone, danazol and pregnenolone-danazol-ethylendiamine (PDE) on perfusion pressure. The results showed that PDE significantly increase the perfusion pressure ( $p = 0.05$ ) through of time (3 - 18 min) in comparison with the control conditions, pregnenolone and danazol. Each bar represents the mean  $\pm$  S.E. of 9 experiments.






Figure 3. Activity induced by pregnenolone-danazol-ethylendiamine (PDE) on coronary resistance. The results showed that coronary resistance was high ( $p = 0.05$ ) in presence of PDE in comparison with the control conditions, pregnenolone and danazol. Each bar represents the mean  $\pm$  S.E. of 9 experiments.




**Figure 4.** Effects induced by pregnenolone-danazol-ethylendiamine (PDE) on perfusion pressure through of androgen receptors. Intracoronary boluses (50  $\mu$ l) of PDE [ $10^{-9}$  to  $10^{-4}$  mM] were administered and the corresponding effect on the perfusion pressure was determined. The results showed that PDE increase the perfusion pressure in a dependent dose manner and this effect was not inhibited in presence of flutamide [ $10^{-6}$  mM]. Each bar represents the mean  $\pm$  S.E. of 9 experiments.




**Figure 5.** Effect exerted by pregnenolone-danazol-ethylendiamine (PDE) on perfusion pressure through of  $\alpha_1$  adrenergic receptor. PDE [ $10^{-9}$  to  $10^{-4}$  M] was administered (intracoronary boluses, 50  $\mu$ l) and the corresponding effect on the perfusion pressure was evaluated in absence and presence of prazosin [ $10^{-6}$  mM]. The results showed that activity induced by PDE on perfusion pressure was not inhibited in presence of prazosin. Each bar represents the mean  $\pm$  S.E. of 9 experiments

On the other hand, other experiments showed that PDE increase the perfusion pressure in a dose dependent manner [ $10^{-9}$  to  $10^{-4}$  mM] and this effect was not inhibited in



**Figure 6.** Activity induced by pregnenolone-danazol-ethylendiamine (PDE) on perfusion pressure through of  $\beta_1$ - adrenergic receptor. Intracoronary boluses (50  $\mu$ l) of PDE [ $10^{-9}$  to  $10^{-4}$  mM] were administered and the corresponding effect on the perfusion pressure was evaluated in absence and presence of metoprolol [ $10^{-6}$  mM]. The results showed that activity induced by PDE on perfusion pressure was not inhibited in presence of metoprolol. Each bar represents the mean  $\pm$  S.E. of 9 experiments



**Figure 7.** Effects induced by pregnenolone-danazol-ethylendiamine (PDE) on perfusion pressure through L type calcium channel. The boluses (50  $\mu$ l) of PDE [ $10^{-9}$  to  $10^{-4}$  mM] were administered in absence and presence of nifedipine [ $10^{-6}$  mM]. The results showed that effect induced by PDE on perfusion pressure in presence of nifedipine was inhibited significantly ( $p = 0.06$ ). Each bar represents the mean  $\pm$  SE of 9 experiments

presence of prazosin (Figure 5) and metoprolol (Figure 6) at a concentration of  $10^{-6}$  mM. Alternative experimental indicate that the activity exerted by PDE [ $10^{-9}$  to  $10^{-4}$  mM] on perfusion pressure (Figure 7) in presence of nifedipine at a concentration of  $10^{-6}$  mM was significantly inhibited ( $p = 0.06$ ).

## Discussion

In this study, was evaluated the effect of danazol derivative on blood vessel capacity and coronary resistance translated as changes in perfusion pressure in isolated rat heart (Langendorff model). The results show that danazol derivative significantly increased perfusion pressure over time (3-18 min) compared to the control conditions. It is important to mention that analyzing the possibility of that both danazol and pregnenolone fragments involved in the chemical structure of danazol derivative could be the responsible of the activity induced by this steroid derivative on the perfusion pressure, the effects exerted by pregnenolone and danazol on the perfusion pressure were evaluated to compare with the activity induced by danazol derivative. The results indicate that perfusion pressure was not affected in presence of both danazol and pregnenolone in comparison with the control conditions. Those experimental data indicate that the steroid derivative induce effects on perfusion pressure, which could consequently bring modifications in coronary resistance as it happens in another type of steroid derivatives<sup>20-23</sup>. To test this hypothesis, we evaluated the effects induced by danazol derivative on coronary resistance. We found that coronary resistance was increased by the danazol derivative in comparison with pregnenolone, danazol and control conditions. These data suggest that steroid derivative exerts effect on vascular tone. To characterize the molecular mechanism of this phenomenon we noted the reports of some investigations<sup>27,28</sup> which indicate that some androgens induce its effect on blood pressure via activation of the androgen receptor<sup>27</sup>. For this reason, we used flutamide (androgen receptor blocker) to determine if the effects of danazol derivative on perfusion pressure were via the androgen receptor activation as in the case of other androgen derivatives<sup>21-23</sup>. Our results showed that the effects of danazol derivative were not inhibited by flutamide, suggesting that the molecular mechanism is not via the androgen-receptor.

On the other hand, analyzing data obtained in this study and the report on the molecular mechanism proposed by Kumai and coworkers<sup>28</sup> which suggests that some steroids can exert an indirect tonic effect on adrenal catecholamine synthesis and secretion. In Addition, of other studies which suggest that androgens stimulate the increased expression of adrenergic receptors (in some cellular lines), which has an important role in the development or maintenance of elevated blood pressure<sup>29</sup>. To evaluate this hypothesis in this study, the effect exerted by danazol derivative on perfusion pressure was evaluated in absence or presence of prazosin ( $\alpha_1$  adrenoreceptor antagonist) and metoprolol (selective  $\beta_1$  receptor blocker). Our results

showed that the effect induced by the danazol derivative was not inhibited in presence of these compounds. These data indicate that molecular mechanism involved in the effects of this danazol derivative on perfusion pressure is not through adrenergic activity.

Therefore, analyzing experimental data obtained in this study, we also considered validating the effect induced by some steroids on perfusion pressure *via* calcium-channels<sup>30</sup>. To evaluate this hypothesis in this study, the effect induced by danazol derivative on perfusion pressure was evaluated in absence or presence nifedipine (antagonist *type* L calcium-channel). The results showed that activity of steroid derivative in presence of nifedipine was blocked significantly. These data are similar to some reports<sup>23</sup> which showed that the pressor effect of some steroid derivatives is partially reversed by the subsequent administration of nifedipine. In conclusion, the results obtained suggest that activity induced by danazol derivative on perfusion pressure and vascular resistance is dependent upon its chemical structure. This phenomenon involves activation of the *L-type calcium channel* via a non-genomic molecular mechanism

## Acknowledgment

We are grateful to Enriqueta Valverde Anzurez, Glafira Valverde Anzurez, and Gloria Velazquez Zea for technical assistance.

## References

1. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. *Arterioscler* 1989; 9: 119-132.
2. Mahoney L, Burns T, Stanford W. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults. *J Am Coll Cardiol* 1996; 27: 277-284.
3. Khoury S, Yarows S, O'Brien T, et al. Ambulatory blood pressure monitoring in a nonacademic setting: effects of age and sex. *Am J Hypertens* 1992; 5: 616-623.
4. Wiinberg N, Hoegholm A, Christensen H, et al. 24-h Ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. *Am J Hypertens* 1995; 8: 978-986.
5. Barrett C, Khaw K. Endogenous sex hormones and cardiovascular disease in men. A prospective populationbased study. *Circulation* 1988; 78: 539-545.
6. Figueroa-Valverde L, Maldonado G, Díaz E, Ozaeta R. Evaluación de la actividad biológica de la testosterona sobre la presión de perfusión en un modelo de corazón aislado. *Rev Inter Androl* 2008; 6(4): 236-241.
7. Svartberg J, Muhlenl D, Schirmer H, et al. Association of endogenous testosterone with blood pressure and left

- ventricular mass in men. The Tromsø Study. *Eur J Endocrinol* 2004; 150: 65-71.
8. Pears J, Sandercock P. Benign intracranial hypertension associated with danazol. *Scott Med J* 1990; 35:49.
  9. Wu Y, Chen S, Li T, et al. Intracranial hypertension associated with danazol withdrawal: a case report. *Acta Neurol Taiwan* 2007; 16: 173-176.
  10. Bretza J, Novey H, Vaziri N. Hypertension: a complication of danazol therapy. *Arch Intern Med* 1980; 140: 1379-1380.
  11. Alvarado R, Liu J, Zwolak R. Danazol and limb-threatening arterial thrombosis: two case reports. *J Vasc Surg* 2001; 34: 1123-1126.
  12. Figueroa-Valverde L, Diaz-Ku E, Díaz-Cedillo F, et al. Effects of danazol and danazol hemisuccinate on perfusion pressure and vascular resistance. *Acta Bioquím Clín Latinoam* 2010; 44 (1): 37-45.
  13. Figueroa-Valverde L, Luna L, Castillo-Henkel C, et al. Synthesis and evaluation of the cardiovascular effects of two, membrane impermeant, macromolecular complexes of dextran-testosterone. *Steroids* 2002; 67: 611-619.
  14. Kontula K, Seppanen P, Duyne P, et al. Effect of a nonsteroidal antiandrogen, flutamide, on androgen receptor dynamics and ornithine decarboxylase gene expression in mouse kidney. *Endocrinol* 1985; 116: 226-233.
  15. Graham R, Oates H, Stoker L, et al. Alpha blocking action of the antihypertensive agent, prazosin. *J Pharmacol Exper Ther* 1977; 201:747-252.
  16. Bengtsson C, Johnsson G, Regårdh C. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. *Clin Pharmacol Ther* 1975; 17: 400-408.
  17. Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. *Am J Cardiol* 1980; 46: 1047-1058.
  18. Jayo M, Cisneros F. Guide for the Care and Use of laboratory animals, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, D.C.: National Academy Press; 1996.
  19. Figueroa-Valverde L, Díaz-Cedillo F, López-Ramos M, et al. Synthesis of pregnenolone-danazol-ethylendiamine conjugate: relationship between descriptors logP,  $\pi$ ,  $R_m$  and  $V_m$  and its antibacterial activity in *S. aureus* and *V. cholerae*. *Med Chem Res* 2010, DOI: 10.1007/s00044-010-9408-0.
  20. Ceballos G, Figueroa L, Rubio I, et al. Acute and Non-genomic Effects of Testosterone on Isolated and Perfused Rat Heart. *J Cardio Pharmacol* 1999; 33:691-697.
  21. Figueroa-Valverde L, Díaz-Cedillo F, Diaz-Ku E, et al. Effect induced by hemisuccinate of pregnenolone on perfusion pressure and vascular resistance in isolated rat heart. *African J Pharmacy Pharmacol* 2009; 3(5): 234-241.
  22. Figueroa Valverde L, Ceballos-Reyes G, Díaz-Cedillo F, et al. Biological activity of progesterone-dihydropyridimidine derivative on perfusion pressure and coronary resistance in isolated rat heart. *African J Pharmacy Pharmacol* 2010; 4 (4):170-177.
  23. Figueroa L, Díaz F, Camacho A, et al. Actividad inducida por androsterona y hemisuccinato de androsterona sobre la presión de perfusión y la resistencia vascular. *Biomédica* 2009; 29: 625-634.
  24. Drew G, Witing S. Evidence for a-adrenoceptor two in distinct vascular types of postsynaptic smooth muscle *in vivo*. *Br J Pharmacol* 1979; 67: 207-215.
  25. Rajala G, Kolesari G, Kuhlmann R, et al. Ventricular blood pressure and cardiac output changes in epinephrine- and metoprolol-treated chick embryos. *Exp Teratol* 1988; 38: 291-296.
  26. Hocht C, Opezzo J, Gorzalczany S, et al. Una aproximación cinética y dinámica de metildopa en ratas con coartación aórtica mediante microdiálisis. *Rev Arg Cardiol* 1999; 67: 769-773.
  27. Ely D, Salisbury R, Hadi D, et al. Androgen receptor and the testes influence hypertension in a hybrid rat model. *Hypertension* 1991; 17: 1104-1110.
  28. Kumai T, Tanaka M, Watanabe M, et al. Influence of androgen on tyrosine hydroxylase mRNA in adrenal medulla of spontaneously hypertensive rats. *Hypertension* 1995; 26: 208-212.
  29. Lilley J, Golden J, Stone R. Adrenergic regulation of blood pressure in chronic renal failure. *J Clin Invest* 1976; 57:1190-1200.
  30. Pham T, Robinson R, Danilo P, et al. Effects of gonadal steroids on gender-related differences in transmural dispersion of L-type calcium current. *Cardiovasc Res* 2002; 53:752-762.

#### Correspondence to:

Figueroa-Valverde Lauro  
 Laboratorio de Investigación de la Facultad de Ciencias Químico-Biológicas  
 Universidad Autónoma de Campeche  
 Av. Agustín Melgar  
 Col Buenavista C.P.24039 Campeche Cam.  
 México.

*Activity induced by a danazol derivative on perfusion pressur.....*